Tag Archives: GSK

GSK Goes DTC for London Olympics

By Julian Upton | Published: July 24, 2012
It’s an unusual sight in the UK — a television commercial for a Big Pharma company. But among the cultural and commercial innovations being attributed to the London Olympic Games is GSK’s first UK consumer-facing corporate brand campaign, showcasing its anti-doping operations. The TV ad debuted on July 16; this week, the company’s campaign went [...]
Posted in Advertising, Europe, Global | Also tagged , , , , | 2 Comments

Comply or Die: Introducing GSK's New Corporate Integrity Agreement

By Ben Comer | Published: July 6, 2012
Big pharma talks a lot about the changing business model and placing a new emphasis on patients, but the fact remains that quantity of medicines sold, not quality of care provided, is how to get paid (and how to keep investors happy). Despite its egalitarian trappings, the healthcare “ecosystem” is still dominated by the [...]
Posted in Agency Insight, Corporate Responsibility, Legal, Marketing, Regulatory, Sales, Strategy, compliance | Also tagged , , , , , , , , , | Leave a comment

GSK: A Rebuffed Suitor for the Moment

By Guest Blogger | Published: April 25, 2012
By Patricia Van Arnum. Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.  Although rejecting GSK’s initial bid, HGS kept the door open for other suitors, including again GSK. HGS has authorized its board of directors to explore strategic alternatives for the company, including a potential sale. [...]
Posted in Deals, Guest Blog | Also tagged , , , | 1 Comment

UK Pharma/Bio Responds to 'Predictable' Budget

By Julian Upton | Published: March 21, 2012
UK pharma and biopharma was quick to respond positively to the Chancellor of the Exchequer’s annual Budget speech last week, despite some industry disappointment at a fiscal program widely derided as safe, neutral, and, in Andrew Goodwin of Ernst & Young’s words, “one of the most predictable” of recent times. 
Posted in Global | Also tagged , , , , | Leave a comment

GlaxoSmithKline Recalls Antihypertensive Drug Made at Novartis Facility

By Guest Blogger | Published: March 1, 2012
By Patricia Van Arnum. GlaxoSmithKline is recalling 394,230 bottles containing its antihypertensive drug DynaCirc CR (isradipine) controlled-release tablets, according to a Feb. 22, 2012, FDA enforcement report. The lots are being recalled due to concerns regarding the level of cGMP compliance and procedural controls related to line clearance during the packing process at the Lincoln, Nebraska, [...]
Posted in Regulatory, Safety | Also tagged , , | 1 Comment